Delving into the Latest Updates on MR-228 with Synapse

Author: Karim, Marcus M ; Huang, Kai ; Ilinykh, Philipp A ; Fouch, Mallorie E ; Kimble, James B ; Parekh, Diptiben V ; Bukreyev, Alexander ; Zeitlin, Larry ; Santos, Rodrigo I ; Alter, Galit ; Davidson, Edgar ; Saphire, Erica Ollmann ; Crowe, James E ; Meyer, Michelle ; Pietzsch, Colette A ; Kuzmina, Natalia A ; Liang, Jenny ; Gilchuk, Pavlo ; Gunn, Bronwyn M

Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae. MARV causes severe disease in humans with high fatality. We previously isolated a large panel of monoclonal antibodies (mAbs) from B cells of a human survivor with previous naturally acquired MARV infection. Here, we characterized functional properties of these mAbs and identified non-neutralizing mAbs targeting the glycoprotein (GP) 2 portion of the mucin-like domain (MLD) of MARV GP, termed the wing region. One mAb targeting the GP2 wing, MR228, showed therapeutic protection in mice and guinea pigs infected with MARV. The protection was mediated by the Fc fragment functions of MR228. Binding of another GP2 wing-specific non-neutralizing mAb, MR235, to MARV GP increased accessibility of epitopes in the receptor-binding site (RBS) for neutralizing mAbs, resulting in enhanced virus neutralization by these mAbs. These findings highlight an important role for non-neutralizing mAbs during natural human MARV infection.

100 Deals associated with MR-228

Login to view more data